Готові списки джерел за темами / CD44 antigen

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Добірка наукової літератури з теми "CD44 antigen"

Автор: Grafiati
Опубліковано: 4 червня 2021
Оновлено: 5 лютого 2022

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "CD44 antigen".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "CD44 antigen"

1

Escribano, Luis, Alberto Orfao, Jesús Villarrubia, Beatriz Díaz-Agustín, Carlos Cerveró, Agustín Rios, José L. Velasco, Juana Ciudad, José L. Navarro, and Jesús F. San Miguel. "Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples." Analytical Cellular Pathology 16, no. 3 (1998): 151–59. http://dx.doi.org/10.1155/1998/341340.

Повний текст джерела
Анотація:
The goal of the present paper was to define the immunophenotype of bone marrow mast cells (BMMC) from healthy controls and patients with hematologic malignancies (HM) based on the use of multiple stainings with monoclonal antibodies analyzed by flow cytometry. Our results show that BMMC from both groups of individuals display a similar but heterogenous immunophenotype. The overall numbers of BMMC are higher in the HM group of individuals (p= 0.08). Three patterns of antigen expression were detected: (1) markers constantly positive in all cases analyzed (CD9, CD29, CD33, CD43, CD44, CD49d, CD49e, CD51, CD71, CD117, and FcεRI), (2) antigens that were constantly negative (CD1a, CD2, CD3, CD5, CD6, CD11a, CD14, CD15, CD16, CD19, CD20, CD21, CD23, CD25, CD30, CD34, CD38, CD41a, CD42b, CD65, CD66b, HLA-DR, and CD138), and (3) markers that were positive in a variable proportion of cases – CD11b (50%), CD11c (77%), CD13 (40%), CD18 (20%), CD22 (68%), CD35 (27%), CD40 (67%), CD54 (88%) and CD61 (40%). In addition, BMMC from all cases explored were CD45+, and this antigen was expressed at an intensity similar to that of mature granulocytes.In summary, our results show that BMMC from both healthy controls and HM patients display a relatively heterogenous immunophenotype. Interestingly, we have observed clear differences between the immunophenotype of BMMC and MC from other tissues. This could be due either to the heterogeneity of human MC according to their tissue localization or to the sensitivity of the method used for antigen detection.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Shirure, Venktesh S., Tiantian Liu, Luis F. Delgadillo, Chaz M. Cuckler, David F. J. Tees, Fabian Benencia, Douglas J. Goetz, and Monica M. Burdick. "CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions." American Journal of Physiology-Cell Physiology 308, no. 1 (January 1, 2015): C68—C78. http://dx.doi.org/10.1152/ajpcell.00094.2014.

Повний текст джерела
Анотація:
Adhesion of circulating tumor cells to vascular endothelium is mediated by specialized molecules that are functional under shear forces exerted by hematogenous flow. Endothelial E-selectin binding to glycoforms of CD44 mediates shear-resistant cell adhesion in numerous physiological and pathological conditions. However, this pathway is poorly understood in breast cancer and is the focus of the present investigation. All breast cancer cell lines used in this study strongly expressed CD44. In particular, BT-20 cells expressed CD44s and multiple CD44v isoforms, whereas MDA-MB-231 cells predominantly expressed CD44s but weakly expressed CD44v isoforms. CD44 expressed by BT-20, but not MDA-MB-231, cells possessed E-selectin ligand activity as detected by Western blotting and antigen capture assays. Importantly, CD44 expressed by intact BT-20 cells were functional E-selectin ligands, regulating cell rolling and adhesion under physiological flow conditions, as found by shRNA-targeted silencing of CD44. Antigen capture assays strongly suggest greater shear-resistant E-selectin ligand activity of BT-20 cell CD44v isoforms than CD44s. Surprisingly, CD44 was not recognized by the HECA-452 MAb, which detects sialofucosylated epitopes traditionally expressed by selectin ligands, suggesting that BT-20 cells express a novel glycoform of CD44v as an E-selectin ligand. The activity of this glycoform was predominantly attributed to N-linked glycans. Furthermore, expression of CD44v as an E-selectin ligand correlated with high levels of fucosyltransferase-3 and -6 and epithelial, rather than mesenchymal, cell phenotype. Together, these data demonstrate that expression of CD44 as a functional E-selectin ligand may be important in breast cancer metastasis.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

HERMIDA-GÓMEZ, TAMARA, ISAAC FUENTES-BOQUETE, MARIA JOSÉ GIMENO-LONGAS, EMMA MUIÑOS-LÓPEZ, SILVIA DÍAZ-PRADO, FRANCISCO JAVIER de TORO, and FRANCISCO JAVIER BLANCO. "Quantification of Cells Expressing Mesenchymal Stem Cell Markers in Healthy and Osteoarthritic Synovial Membranes." Journal of Rheumatology 38, no. 2 (November 15, 2010): 339–49. http://dx.doi.org/10.3899/jrheum.100614.

Повний текст джерела
Анотація:
Objective.To quantify cells expressing mesenchymal stem cell (MSC) markers in synovial membranes from human osteoarthritic (OA) and healthy joints.Methods.Synovial membranes from OA and healthy joints were digested with collagenase and the isolated cells were cultured. Synovial membrane-derived cells were phenotypically characterized for differentiation experiments using flow cytometry to detect the expression of mesenchymal markers (CD29, CD44, CD73, CD90, CD105, CD117, CD166, and STRO-1) and hematopoietic markers (CD34 and CD45). Chondrogenesis was assessed by staining for proteoglycans and collagen type II, adipogenesis by using a stain for lipids, and osteogenesis by detecting calcium deposits. Coexpression of CD44, CD73, CD90, and CD105 was determined using immunofluorescence.Results.Cells expressing MSC markers were diffusely distributed in OA synovial membranes; in healthy synovial membrane these cells were localized in the subintimal zone. More numerous MSC markers in OA synovial membranes were observed in cells also expressing the CD90 antigen. FACS analysis showed that more than 90% of OA synovial membrane-derived cells were positive for CD44, CD73, and CD90, and negative for CD34 and CD45. OA synovial membrane-derived cells were also positive for CD29 (85.23%), CD117 (72.35%), CD105 (45.5%), and STRO-1 (49.46%). Micropellet analyses showed that the culture of cells with transforming growth factor-ß3 stimulated proteoglycan and collagen type II synthesis.Conclusion.Synovial membranes from patients with OA contain more cells positive for CD44, CD90, and CD105 antigens than those from joints with undamaged cartilage.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Sallusto, F., and A. Lanzavecchia. "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha." Journal of Experimental Medicine 179, no. 4 (April 1, 1994): 1109–18. http://dx.doi.org/10.1084/jem.179.4.1109.

Повний текст джерела
Анотація:
Using granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin 4 we have established dendritic cell (DC) lines from blood mononuclear cells that maintain the antigen capturing and processing capacity characteristic of immature dendritic cells in vivo. These cells have typical dendritic morphology, express high levels of major histocompatibility complex (MHC) class I and class II molecules, CD1, Fc gamma RII, CD40, B7, CD44, and ICAM-1, and lack CD14. Cultured DCs are highly stimulatory in mixed leukocyte reaction (MLR) and are also capable of triggering cord blood naive T cells. Most strikingly, these DCs are as efficient as antigen-specific B cells in presenting tetanus toxoid (TT) to specific T cell clones. Their efficiency of antigen presentation can be further enhanced by specific antibodies via FcR-mediated antigen uptake. Incubation of these cultured DCs with tumor necrosis factor alpha (TNF-alpha) or soluble CD40 ligand (CD40L) for 24 h results in an increased surface expression of MHC class I and class II molecules, B7, and ICAM-1 and in the appearance of the CD44 exon 9 splice variant (CD44-v9); by contrast, Fc gamma RII is markedly and sometimes completely downregulated. The functional consequences of the short contact with TNF-alpha are in increased T cell stimulatory capacity in MLR, but a 10-fold decrease in presentation of soluble TT and a 100-fold decrease in presentation of TT-immunoglobulin G complexes.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Kansas, GS, MJ Muirhead, and MO Dailey. "Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans." Blood 76, no. 12 (December 15, 1990): 2483–92. http://dx.doi.org/10.1182/blood.v76.12.2483.2483.

Повний текст джерела
Анотація:
Abstract We have used three-color flow cytometry to investigate the pattern of expression of the CD11/CD18, CD44, and leukocyte adhesion molecule 1 (LAM-1) adhesion molecules during myeloid and erythroid differentiation in humans. The earliest myeloid cells, identified as CD33loCD15-, were exclusively CD44hi but contained both leukocyte function-associated antigen 1 (LFA-1hi) and LFA-1lo cells, as well as LAM-1+ and LAM-1- cells. This CD33loCD15- myeloid subpopulation expressed only low levels of CD11c and failed to express CD11b, CD14, or any lymphoid (CD3, CD16, CD19) antigens or glycophorin. Commitment to monocyte differentiation, suggested by the presence of an LFA-1hi CD11c+ subset within the CD33loCD15- subpopulation, was clearly signaled by upregulation of CD33; these monocyte-lineage committed cells were exclusively CD33hi, CD44hi, CD11ahi, CD11c+, and exhibited a broad range of intensity of CD15 expression. Later stages of monopoiesis were identified by acquisition of CD11b, and subsequently of CD14. Myeloid cells committed to granulopoiesis remained LFA-1lo, and underwent a sharp upregulation of CD15 along with downregulation of both CD33 and CD44. Successive stages of granulocyte development were marked by expression of CD11b and, subsequently, of CD16. The earliest cells capable of erythroid differentiation were CD44hi, LFA-1lo, and LAM-1+. Both LFA-1 and LAM-1 were lost before the onset of glycophorin (glyco) expression, whereas CD44 expression remained high on glyco+ cells, which also expressed CD45. CD44 expression was intermediate on glyco+ CD71+ cells, and low on glyco+ CD45- CD71- cells, similar to normal, circulating erythrocytes. Our results allow us to phenotypically define discrete stages in the normal development of monocytes, neutrophils, and erythrocytes. The expression of LFA-1, LAM-1, and high levels of CD44 on the most primitive hematopoietic cells detectable by flow cytometry suggests that at least some of these molecules are critically involved in leukocyte adhesion during development.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kansas, GS, MJ Muirhead, and MO Dailey. "Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans." Blood 76, no. 12 (December 15, 1990): 2483–92. http://dx.doi.org/10.1182/blood.v76.12.2483.bloodjournal76122483.

Повний текст джерела
Анотація:
We have used three-color flow cytometry to investigate the pattern of expression of the CD11/CD18, CD44, and leukocyte adhesion molecule 1 (LAM-1) adhesion molecules during myeloid and erythroid differentiation in humans. The earliest myeloid cells, identified as CD33loCD15-, were exclusively CD44hi but contained both leukocyte function-associated antigen 1 (LFA-1hi) and LFA-1lo cells, as well as LAM-1+ and LAM-1- cells. This CD33loCD15- myeloid subpopulation expressed only low levels of CD11c and failed to express CD11b, CD14, or any lymphoid (CD3, CD16, CD19) antigens or glycophorin. Commitment to monocyte differentiation, suggested by the presence of an LFA-1hi CD11c+ subset within the CD33loCD15- subpopulation, was clearly signaled by upregulation of CD33; these monocyte-lineage committed cells were exclusively CD33hi, CD44hi, CD11ahi, CD11c+, and exhibited a broad range of intensity of CD15 expression. Later stages of monopoiesis were identified by acquisition of CD11b, and subsequently of CD14. Myeloid cells committed to granulopoiesis remained LFA-1lo, and underwent a sharp upregulation of CD15 along with downregulation of both CD33 and CD44. Successive stages of granulocyte development were marked by expression of CD11b and, subsequently, of CD16. The earliest cells capable of erythroid differentiation were CD44hi, LFA-1lo, and LAM-1+. Both LFA-1 and LAM-1 were lost before the onset of glycophorin (glyco) expression, whereas CD44 expression remained high on glyco+ cells, which also expressed CD45. CD44 expression was intermediate on glyco+ CD71+ cells, and low on glyco+ CD45- CD71- cells, similar to normal, circulating erythrocytes. Our results allow us to phenotypically define discrete stages in the normal development of monocytes, neutrophils, and erythrocytes. The expression of LFA-1, LAM-1, and high levels of CD44 on the most primitive hematopoietic cells detectable by flow cytometry suggests that at least some of these molecules are critically involved in leukocyte adhesion during development.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Parsons, SF, J. Jones, DJ Anstee, PA Judson, B. Gardner, E. Wiener, J. Poole, N. Illum, and SN Wickramasinghe. "A novel form of congenital dyserythropoietic anemia associated with deficiency of erythroid CD44 and a unique blood group phenotype [In(a-b- ), Co(a-b-)]." Blood 83, no. 3 (February 1, 1994): 860–68. http://dx.doi.org/10.1182/blood.v83.3.860.860.

Повний текст джерела
Анотація:
Abstract We have used a panel of well-characterized monoclonal antibodies (MoAbs) to examine the blood cells of a patient with a novel form of congenital dyserythropoietic anemia (CDA) characterized by intra- erythroblastic and intra-erythrocytic membranous inclusions. Twelve antibodies defining three nonoverlapping epitope groups on the extracellular domain of CD44 all failed to react with the red blood cells (RBCs) of the patient. A rabbit antibody to the cytoplasmic domain of CD44 from normal RBCs failed to react with the patient's RBC ghosts. In contrast, the patient's lymphocytes, granulocytes, and monocytes showed apparently normal CD44 expression. Bone marrow preparations stained with CD44 antibodies and visualized with 125I antimouse Ig (F(ab')2) followed by autoradiography showed positive staining of lymphocytes and myeloid cells but not of most orthotolidine- positive erythroblasts. The patient's RBCs also gave weaker than normal reactions with MoAbs of anti-LWab specificity while MoAbs to glycophorins A, B, and C, Rh polypeptides, CD47, CD55, CD58, CD59, acetylcholinesterase, and Lutheran and Kell glycoproteins all gave normal reactions. Agglutination tests with human blood grouping sera demonstrated that the RBCs of the patient have the unique phenotype In(a-b-), Co(a-b-) and that they also lack the high incidence RBC antigen AnWj. The phenotype In(a-b-) would be expected because these antigens are known to be expressed on CD44. There is also some evidence associating the AnWj antigen with CD44. However, the CO blood group locus is on chromosome 7p whereas that for CD44 is on chromosome 11p. Quantitative binding assays using 125I-labeled Fab fragments of CD44 antibodies did not show any evidence for reduced levels of CD44 on RBCs from the parents of the patient or from her unaffected sister. The parents and sister had the common Colton blood group phenotype [Co(a+b- )]. Neither deficiency of CD44 nor absence of Colton antigens are general features of CDA because erythrocytes from patients with CDA I, CDA II, CDA III, and two other unclassified CDAs had normal expression of CD44 and normal Colton blood group phenotypes. Further analysis of the defect(s) present in the patient's erythroid cells may provide useful information regarding membrane assembly and the regulation of differentiation in normal erythroid cells.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Parsons, SF, J. Jones, DJ Anstee, PA Judson, B. Gardner, E. Wiener, J. Poole, N. Illum, and SN Wickramasinghe. "A novel form of congenital dyserythropoietic anemia associated with deficiency of erythroid CD44 and a unique blood group phenotype [In(a-b- ), Co(a-b-)]." Blood 83, no. 3 (February 1, 1994): 860–68. http://dx.doi.org/10.1182/blood.v83.3.860.bloodjournal833860.

Повний текст джерела
Анотація:
We have used a panel of well-characterized monoclonal antibodies (MoAbs) to examine the blood cells of a patient with a novel form of congenital dyserythropoietic anemia (CDA) characterized by intra- erythroblastic and intra-erythrocytic membranous inclusions. Twelve antibodies defining three nonoverlapping epitope groups on the extracellular domain of CD44 all failed to react with the red blood cells (RBCs) of the patient. A rabbit antibody to the cytoplasmic domain of CD44 from normal RBCs failed to react with the patient's RBC ghosts. In contrast, the patient's lymphocytes, granulocytes, and monocytes showed apparently normal CD44 expression. Bone marrow preparations stained with CD44 antibodies and visualized with 125I antimouse Ig (F(ab')2) followed by autoradiography showed positive staining of lymphocytes and myeloid cells but not of most orthotolidine- positive erythroblasts. The patient's RBCs also gave weaker than normal reactions with MoAbs of anti-LWab specificity while MoAbs to glycophorins A, B, and C, Rh polypeptides, CD47, CD55, CD58, CD59, acetylcholinesterase, and Lutheran and Kell glycoproteins all gave normal reactions. Agglutination tests with human blood grouping sera demonstrated that the RBCs of the patient have the unique phenotype In(a-b-), Co(a-b-) and that they also lack the high incidence RBC antigen AnWj. The phenotype In(a-b-) would be expected because these antigens are known to be expressed on CD44. There is also some evidence associating the AnWj antigen with CD44. However, the CO blood group locus is on chromosome 7p whereas that for CD44 is on chromosome 11p. Quantitative binding assays using 125I-labeled Fab fragments of CD44 antibodies did not show any evidence for reduced levels of CD44 on RBCs from the parents of the patient or from her unaffected sister. The parents and sister had the common Colton blood group phenotype [Co(a+b- )]. Neither deficiency of CD44 nor absence of Colton antigens are general features of CDA because erythrocytes from patients with CDA I, CDA II, CDA III, and two other unclassified CDAs had normal expression of CD44 and normal Colton blood group phenotypes. Further analysis of the defect(s) present in the patient's erythroid cells may provide useful information regarding membrane assembly and the regulation of differentiation in normal erythroid cells.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Mancuso, Patrizia, Ines Martin Padura, Giuliana Gregato, Paola Marighetti, Angelica Calleri, Chiara Corsini, Giancarlo Pruneri, Visnu Lohsiriwat, Jean Yves Petit, and Francesco Bertolini. "CD45-CD34+ Endothelial Progenitor Cells (EPCs) from Human Adipose Tissue Promote Tumor Growth and Metastases." Blood 118, no. 21 (November 18, 2011): 2208. http://dx.doi.org/10.1182/blood.v118.21.2208.2208.

Повний текст джерела
Анотація:
Abstract Abstract 2208 A catalytic role has been proposed in neoplastic angiogenesis and cancer progression for bone marrow-derived endothelial progenitor cells (EPCs). However, in preclinical and clinical studies the quantitative role of marrow-derived EPCs in cancer vascularization was found to be extremely variable. Adipose tissue represents an attractive source of autologous adult stem cells due to its abundance and surgical accessibility. Lipotransfer aspirates (LAs) from patients undergoing breast reconstruction after breast cancer surgery were analyzed by six colors flow cytometry and tissue culture. After collagenase digestion, cells were stained with the nuclear binding antigen Syto16 and 7-AAD and with CD34, CD45, CD133, CD31, CD140b, CD105, CD90, CD44, CD13, CD144, CD10, CD29, CD109, CD117, CD146,CD16, CD11c, CD14, CD38, CXCR4, VEGFR-1, VEGFR-2, VEGFR-3, Tie-2. The absolute count of CD45-CD34+ cells was obtained using reference beads in Trucount tubes (BD, Mountain View, CA). LAs were found to contain a large amount of CD45-CD34+ cells fulfilling the most recent criteria for EPC identification. These CD45-CD34+ cells included two subpopulations: CD45-CD34++ CD13+ CD140b+ CD44+ CD90++ cells and CD45-CD34+ CD31+CD105+ cells. We found in the adipose tissue about 263 fold more CD45-CD34+ EPCs/mL when compared to the bone marrow. In particular, the median of CD45-CD34+CD31- cells/mL was 181,046 (range 35,970–465,357), and the median of CD45-CD34+CD31+ cells/mL was 76,946 (range13,982-191,287). When compared to marrow-derived CD34+ cells, purified CD45-CD34+ adipose cells expressed similar levels of stemness-related genes such as NANOG, SOX2, Lin28 and significantly increased levels of angiogenesis-related genes such as CD144, VEGFR2, ALK-1. In vitro, CD45-CD34+ cells generated mature endothelial cells and capillary tubes as well as mature mesenchymal cells. When coinjected with triple negative human breast cancer MDA-MB-436 and HCC1937 cells in the mammary fat of a murine model of human breast cancer, purified CD45-CD34+ cells significantly increased tumor growth, and immunohistochemistry studies demonstrated the presence of human CD31+, CD34+, CD105+ endothelial cells lining the vessels of orthotopic breast cancers growing in mice co-injected with human adipose tissue-derived CD45-CD34+ cells. Moreover, in a mouse model of breast cancer metastatization we found an increased number of lung and axillary lymph node metastases when purified CD34+ WAT cells were injected into the third mammary fat pad after the primary tumor resection. In conclusion our data demonstrate that the phenotype of adipose derived EPCs is consistent with that reported for both bone marrow and circulating EPCs, but their frequency in adipose tissue is more than 250 fold higher. Further studies are ongoing to clarify what cell populations residing in the adipose tissue can be used safely for breast reconstruction and what are at risk for supporting the growth of otherwise quiescent cancer cells still resident after surgery. Disclosures: No relevant conflicts of interest to declare.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Rappa, G., F. Anzanello, and A. Lorico. "CD24 expression and breast cancer stem cell phenotype." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 11106. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11106.

Повний текст джерела
Анотація:
11106 Background: Several studies suggest the existence of breast cancer-initiating cells (BCIC), responsible for tumor development and progression. Initial reports that only the CD44+CD24−/low subpopulation contains BCIC have been challenged by subsequent studies. We examined the relationship between CD24 and biological properties of breast cancer cells. Methods: MA-11 breast carcinoma cells, originating from bone marrow micrometastases, are CD44+ and have an heterogeneous expression of CD24 (214,000/cell; range 0–1,120,000). We have previously reported that upon in vitro culture as mammospheres under stem cell-like conditions, MA-11 cells acquired increased tumorigenicity and a CD44+CD24−/low phenotype. We have now investigated the relationship between CD24 expression and tumorigenicity in the MA-11 model. Results: Upon passage of MA-11 mammospheres in adherent culture, cells rapidly re-expressed CD 24. The rapid increase in CD24 was consistent with antigen up-regulation, not selection of CD24−/low cells. Exposure of adherent MA-11 cells to imatinib for 72h resulted in a reversible decrease in CD24 from 214,000 to 15,800/cell. CD44+CD24−/low cells, sorted by flow cytometry, generated CD44+CD24high, and CD44+CD24highgenerated CD44+CD24−/low. Immediately after sorting, >90% CD44+CD24−/low cells were in G0/G1. After 24–48 h in culture, cell cycle distribution, growth rate and invasiveness of the sorted cell populations were equivalent. Upon injection and s.c. growth, CD24 expression of CD44+CD24−/low populations and clones increased from 10,000 to 220,000/cell. Similarly, CD44+CD24−/low clones derived from human MCF-7 breast carcinoma cells formed tumors containing >99% CD44+CD24high cells. The average number of CD24 per cell was equivalent for tumors formed upon injection of CD44+CD24−/low, CD44+CD24+, mammosphere-derived cells or parental adherent MA-11 cells. The tumorigenic potentials of sorted CD44+CD24−/low, CD44+CD24−/lowsub-populations and clones in nu/nu mice were equivalent. Conclusions: CD44+CD24−/low breast cancer cells are not associated with increased tumorigenicity; the high CD24 level of mouse xenografts derived from both CD44+CD24−/low and CD44+CD24hi breast cancer cells suggests an important role for CD24 in tumor growth. No significant financial relationships to disclose.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "CD44 antigen"

1

Varelias, Antiopi. "Studies of CD44 variant isoform expression and function on activated human peripheral blood mononuclear cells and in renal transplantation." Title page, summary and contents only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phv293.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Voort, Robbert van der. "Hepatocyte growth factor, Met, and CD44 a ménage à trois in B cells /." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2000. http://dare.uva.nl/document/55874.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Föger, Niko. "Costimulatory function of CD44 : acting in unison with the T cell receptor." kostenfrei, 2000. http://nbn-resolving.de/urn/resolver.pl?urn=nbn:de:bvb:20-opus-1186.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Lein, Michael Torsten. "Neue Serummarker bei urologischen Malignomen mit dem Schwerpunkt Prostatakarzinom und Anwendung von Proteinase-Inhibitoren in der Therapie des Prostatakarzinoms." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2001. http://dx.doi.org/10.18452/13730.

Повний текст джерела
Анотація:
Die vorliegende Habilitationsschrift "Neue Serummarker bei urologischen Malignomen mit dem Schwerpunkt Prostatakarzinom und Anwendung von Proteinase-Inhibitoren in der Therapie des Prostatakarzinoms" faßt Ergebnisse zusammen, die ich in den Jahren von 1996 bis 2000 als Erstautor in wissenschaftlichen Artikeln von peer reviewed Zeitschriften veröffentlicht habe. Zusätzlich werden 14 Arbeiten mit ihren Aussagen eingeschlossen, bei denen ich als Koautor beteiligt war. Gegenstand der Habilitationsschrift sind Untersuchungen zur diagnostischen Optimierung des Tumormarkers Prostataspezifisches Antigen (PSA) und zum Expressionsverhalten von CD44-Proteinen bzw. Matrix-Metalloproteinasen (MMPs) als potentielle, neue Marker bei urologischen Karzinomen. Die nachgewiesene Bedeutung der MMPs bei der Tumorprogression und -metastasierung hat mich dazu veranlaßt, tierexperimentelle Studien zur Hemmung der MMP-Aktivität mit synthetischen Inhibitoren in meine Arbeit aufzunehmen. Zielstellung war hierbei die Evaluierung neuer Therapieoptionen beim fortgeschrittenen Tumor. Im Mittelpunkt der Untersuchungen steht das Prostatakarzinom (PCa) als häufigster maligner Tumor des Mannes. 1. Das PSA ist ohne Zweifel der beste Tumormarker in der Diagnostik des PCa. Der Optimierung dieses Markers wird große Bedeutung zugemessen. Dabei werden verschiedene Konzepte verfolgt, wobei die Bestimmung der Isoformen des PSA die zur Zeit erfolgreichste Richtung zu sein scheint. Die Ergebnisse meiner u.a. im Rahmen von Multizenterstudien durchgeführten Untersuchungen belegen den diagnostischen Nutzen der zusätzlichen Bestimmung des f-PSA%, um PCa-Patienten früher zu erkennen und besser gegenüber Patienten mit benigner Prostatahyperplasie (BPH) abgrenzen zu können. Ein weiteres Ergebnis der Untersuchungen zur diagnostischen Validität anderer PSA-Isoformen ist die Feststellung, daß die Bestimmung des gebundenen PSA keinen Vorteil gegenüber dem f-PSA% hat. Widersprüchliche Angaben in der Literatur konnten damit ausgeräumt werden. Diese Ergebnisse veranlaßten die Firma Roche als Kooperationspartner, die Weiterentwicklung eines ACT-PSA Prototyp-Testsystems einzustellen. Die Ergebnisse meiner Untersuchungen zu den PSA-Isoformen haben inzwischen Eingang in den klinischen Alltag gefunden und werden in der Urologischen Klinik der Charité genutzt. Es wurden Entscheidungsgrenzen für den f-PSA%-Wert zur Indikationsstellung von Stanzbiopsien der Prostata als Klinikstandard erarbeitet. 2. Bei verschiedenen urologischen Tumoren wurde das Expressionsverhalten von CD44-Proteinen und MMPs bzw. deren Inhibitoren bestimmt, um eine mögliche Bedeutung bei der Tumorprogression zu erfassen. Diese Untersuchungen sind gleichzeitig Voraussetzung für eine mögliche Anwendung der Komponenten in der Diagnostik und Therapiekontrolle bei diesen Tumorentitäten. Im Gegensatz zu anderen menschlichen Tumoren konnten bei den untersuchten urologischen Tumoren keine veränderten Serumkonzentrationen der CD44-Proteine einschließlich der Varianten nachgewiesen werden. Daher habe ich weiterführende Studien zu den CD44-Proteinen nicht durchgeführt. 3. Im Tumorgewebe sowie im Plasma von Patienten mit PCa und Nierenzellkarzinom konnte ich signifikante Veränderungen von MMPs und deren Inhibitoren nachweisen. Die Situation im Gewebe spiegelt sich zum Teil im Blut der Patienten wider. Diese Beobachtungen beweisen die Bedeutung der MMPs bei der Tumorprogression und -metastasierung. Prinzipiell kann die Bestimmung einzelner MMPs bzw. TIMPs in der Diagnostik von urologischen Tumoren genutzt werden. Die niedrige Sensitivität in der individuellen Erfassung des einzelnen Tumorpatienten schränkt jedoch die praktische Anwendung ein. 4. Die veränderte MMP-Expression bzw. die Dysbalance zwischen MMPs und TIMPs hat mich veranlaßt, synthetische Inhibitoren zur Blockierung der MMP-Aktivität in einem Standardtiermodell des menschlichen PCa einzusetzen. In einer ersten Untersuchung am Dunning-Tumor der Ratte wurde nachgewiesen, daß dieser Tumor MMP9 exprimiert und die Serumkonzentration mit der Tumorgröße korreliert. In weiteren tierexperimentellen Untersuchungen wurde der Einfluß von Batimastat, einem Breitspektrum-Inhibitor der MMPs und einem neuentwickelten, selektiveren Inhibitor (Icol) auf das orthotope Tumorwachstum ermittelt. Beide Substanzen führten zu einer Hemmung des lokalen Tumorwachstums. Durch Applikation von Icol wurde eine Reduzierung des Tumorgewichtes um 90% im Vergleich zu den unbehandelten Kontrolltieren erreicht. Diese Beobachtungen haben eine doppelte Bedeutung. Zum einen beweist die Hemmwirkung von synthetischen MMP-Inhibitoren im Tiermodell die Funktion der MMPs bei der lokalen Tumorprogression. Zum anderen werden durch diese erfolgreichen tierexperimentellen Studien mit neuen Substanzen Voraussetzungen für die klinische Anwendung bei Patienten mit hormonrefraktärem PCa geschaffen.
The aim of my "habilitation thesis" was to evaluate the diagnostic validity of prostate-specific antigen (PSA) in serum and tissue, the serum pattern of CD44 proteins and of the matrix metalloproteinases (MMPs) in serum and tissue of urological malignancies. As MMPs seem to play an important role in tumor progression and metastasis, animal studies were additionally initiated in order to investigate the influence of synthetic inhibitors of MMPs on prostate cancer. 1. PSA is the most important and accurate tumor marker in prostate cancer diagnosis. However, PSA is an organ-specific marker, but is not tumor-specific. Elevated PSA concentrations are seen with non-malignant prostatic diseases like benign prostatic hyperplasia (BPH). Moreover, not all patients with prostate cancer have elevated PSA concentrations. In order to optimize the diagnostic validity of PSA, several concepts have been developed. Determination of the PSA isoforms in serum could help discriminate between prostate cancer and BPH. In various own studies, including a multicenter clinical trial, the determination of free PSA and the calculation the ratio of free PSA to total PSA (fPSA/tPSA) has proven to be a promising tool in prostate cancer diagnosis. Regarding the diagnostic validity of the complexed PSA conflicting data exist. Our results, using a newly developed alpha-1-antichymotrypsin-PSA (ACT-PSA) assay by Roche are contradictory to recent published data. Based on data of a multicenter trial, the determination of ACT-PSA as well as the ACT-PSA to tPSA ratio did not improve the differential diagnostic impact in patients undergoing evaluation for prostate cancer compared to the ratio fPSA/tPSA. 2. In various malignant diseases characteristic alterations in the expression of CD44 proteins and their variants have been observed. In contrast to those observations in other carcinomas, the determination of soluble CD44 proteins in serum is not suitable for detecting and staging patients with urological malignant tumors. Therefore, further investigation have not been performed. 3. Matrix-metalloproteinases (MMP) form a group of endogenous proteases with the common ability to degrade various components of the extracellular matrix. It could be demonstrated that increased levels of MMP are associated with the invasive and metastatic potential in human malignant tumors. However, little is known about the role of MMPs in renal cell carcinoma. In own study significant changes of MMP expression have been observed. Although changes in specific MMPs might be characteristic for renal carcinoma tissues and might be partly reflected in the blood, data shown that even MMP-9 as the best plasma marker, had a low sensitivity in detecting renal cell carcinoma. Increased concentrations of MMP-9 in tumor tissue may have important implications for the therapeutic potential of synthetic inhibitors of MMPs. 4. The importance of inhibitors of MMPs in cancer has been demonstrated in various studies. In own investigations, altered levels of MMPs and their specific inhibitors have been elucidated in prostate cancer. Therefore, a study to evaluate the efficacy of synthetic MMP inhibitors (batimastat, Icol) in a standard prostate cancer animal model was performed. Previously, the high expression of MMP-9 in this prostate cancer (Dunning tumor) compared with normal prostatic tissue could be demonstrated. Batimastat and the newly developed inhibitor Icol reduced the orthotopic tumor weights up to 90% in a dose-dependent manner. This results confirmed the importance of MMPs and their inhibitors in tumor progression. It can be concluded that selective inhibition of MMP activity is a novel therapeutic approach, which bears promise for studies in patients with hormone-refractory prostate cancer.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Bernardi, Maria Auxiliadora. "Expressão de CD44 e CD24 em carcinomas mamários ductais invasivos de acordo com análise dos subtipos moleculares e sua relação com fatores prognósticos." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-27102011-172419/.

Повний текст джерела
Анотація:
Carcinomas de mama são heterogêneos e consistem de diversos tipos celulares. Perfis de expressão gênica usando DNA microarrays identificaram quatro subtipos moleculares fundamentais baseados na expressão de receptores hormonais (estrógeno e progesterona) e de fator de crescimento epidérmico (HER2) (luminal tipo A, luminal tipo B, tumores expressando somente HER2 e triplos negativos) refletindo a heterogeneidade molecular dos carcinomas. Sugeriu-se que esta heterogeneidade advém da presença de células tronco tumorais com a capacidade de se diferenciar ao longo de vias divergentes e outros estudos sugeriram que a presença destas células tronco tumorais pode ser evidenciada pela análise fenotípica de CD44 e CD24. Nosso objetivo foi detectar a freqüência de CD24 e CD44 isolados ou combinados, analisados por imunoistoquímica e sua associação com os subtipos moleculares e com diversos marcadores biológicos em 95 casos de carcinoma ductal infiltrativo organizados em um microarranjo tissular (TMA). Realizamos determinações imunoistoquímicas de CD44, CD24, citoqueratinas (CK5, CK6, CK18), claudina 7 e Ki67. Subgrupos moleculares foram definidos pela expressão imunoistoquímica de RE, RP e HER2. Resultados: Os tumores apresentaram uma maior freqüência dos grupos luminais (49,5%) atribuído à alta expressão de RP ou RE (47,4%), e freqüência menor de tumores triplo negativos (21,5%) e HER2 (9,5%). Os fenótipos CD44+CD24- e CD44-/CD24+ estavam respectivamente presentes em 8,4% e 16,8% dos tumores e o fenótipo duplamente positivo foi predominante (45,3%). Ausência de ambas as proteínas foi evidente em 6,3% dos tumores. Tumores com fenótipo CD44+CD24- (definido como um marcador de células tronco tumorais por estudos in vitro) foram mais comuns em tumores triplos negativos mas não demonstraram nenhum tipo de associação com características clinico-patológicas e demais marcadores. Este fenótipo não foi expresso nos tumores HER2 positivos. O fenótipo duplamente positivo CD44+CD24+ mostrou-se mais freqüente nos subtipos luminais ou com alta expressão de HER2. Os fenótipos (CD44-CD24+ e CD44-CD24-) não mostraram associação com os subgrupos. Tumores expressando CD24+ isolado, com grande freqüência deste marcador (74,7%), mostraram significativa associação com positividade do RE, RP e Ki67 e uma significância marginal com marcadores de diferenciação luminal (CK18 e claudina 7, p = 0,14). Nenhuma associação foi observada com tumores CD44+ quando analisado isoladamente. A expressão de claudina 7 e Ki67 não mostrou associação com os subgrupos e a expressão de CK5 apresentou uma tendência a uma maior negatividade nos subtipos luminais e uma freqüência maior de positividade nos tumores HER2 e triplo negativos. De outro lado, associação da freqüência da expressão positiva de CK18 nos subgrupos luminais foi estatisticamente significativa (p = 0,003). Para se determinar se CD24+ e CD44+ e seus subtipos combinados poderiam afetar a sobrevida global e o intervalo livre da doença preparamos curvas de sobrevida de acordo com Kaplan-Meier que foram analisadas estatisticamente (log rank test). A mediana do período de seguimento das pacientes do nosso estudo foi de 4,8 anos (0,36 10,9 anos). Estas análises não demostraram influência dos fenótipos CD44+CD24- ou CD44+ sobre a sobrevida global ou intervalo livre de doença, mas observamos uma tendência a um prognóstico mais favorável. Interessantemente tumores HER2 positivos não expressaram este fenótipo, sugerindo que outros marcadores de células tronco caracterizam estes tumores. O fenótipo CD44-CD24+ mostrou-se mais freqüente nos tumores luminais, mas não apresentou correlação com marcadores clínico-patológicos ou biológicos analisados. Não houve diferenças significativas com respeito a sobrevida global ou intervalo livre de doença . A expressão de CD24+ isolado associou-se a expressão dos marcadores de diferenciação celular e a uma diminuição do intervalo livre de doença. A sobrevida livre de doença (10 anos) indicou uma percentagem de 94,1% para CD24- e 72,1% para os pacientes CD24+ enquanto a sobrevida global foi de 84,2% para os pacientes CD24- e 72,1% para os pacientes CD24+. Citoqueratinas (CK5, CK18) e Ki67 não influenciaram a sobrevida e o intervalo livre de doença. No entanto a expressão positiva de claudina 7, embora não associada à sobrevida global, foi estatisticamente associada ao decréscimo do intervalo livre da doença (p = 0,05). Conclusão: As características dos tumores CD44+CD24- e sua tendência a associação um prognóstico mais favorável parecem não estar de acordo com as propriedades descritas na literatura para células tronco e enfatizam a necessidade de outros marcadores. A determinação da freqüência de CD44+ e claudina 7 positiva pode contribuir para a análise do prognóstico em carcinoma de mama
Background: Breast carcinomas consist phenotypically of diverse cells and exhibit intra tumoral heterogeneity being stratified in several subgroups based in gene expression profiles or histochemical biomarkers. It was suggested that this heterogeneity is derived in part from the transformation of different subsets of cancer stem cells (CSC) in each intrinsic subgroup. The presence of CSC can be evidenced by phenotypic analysis of CD44 e CD24. This study aimed to identify the CD24 and CD44 immunophenotype within invasive ductal breast carcinoma (IDC) subtypes and determine its influence on prognosis as well as its association with the expression of Ki67, citokeratins (CK5, CK6 and CK18) and claudin-7. Methods: Immuno expression of CD44 and CD24 alone or in combination was investigated in 95 IDC cases arranged in a tissue microarray (TMA). The association with intrinsic subgroups defined as luminal A (ER+, PR+, HER2-), luminal B (ER and or PR+, HER2+), HER2 subtype (ER-, PR-, HER2+) and triple negative (ER-, PR-, HER2-), and the other markers and prognosis was analyzed. Results: CD44+CD24- and CD44-CD24+ were respectively presents in 8.4% and 16.8% of the tumors, a lack of both proteins was detected in 6.3%, while CD44+CD24+ was determined in 45.3% of the tumors. Although there was no significant correlation between subgroups and different phenotypes, the CD44+CD24- phenotype was more common in the basal subgroups but the frequency of this subtype has not been associated with clinical characteristic or biological markers. The phenotype was absent in HER2 tumors whereas luminal tumors are enriched in CD44-CD24+ and CD44+CD24+ cells which did not show associations with clinical/biological markers features. There was also no significant association of the subtypes with the event free (DFS) and overall survival (OS) but the CD44+CD24- phenotype showed a more favorable prognostic as compared to CD44-CD44+ phenotype that showed a worse prognosis (p = 0.26) (median follow up, 4.8 years) CD44+ alone was evident in 57.9%, while CD24+ was positive in 74.7% of the tumors, the latter showing a significant association with ER, PR and Ki67 and a marginal association with CK18 and claudin-7. Expression of claudin-7 and Ki67 did not associate with the cancer subgroups, while a positive association between CK18 and the luminal subgroups was found. CD44+ was not significantly associated with OS (p = 0.684) and DFS (p = 0.386) whereas CD24+ expression was also no significantly associated with OS (p = 0.32) but was associated with a decrease in DFS (p = 0.07). CK5, CK18 and Ki67 expression had no influence in OS or DFS, however claudin-7 positive although not statistically associated with OS, was associated with reduced DFS (p = 0.05). Conclusions: The heterogeneity of cells with several CD44CD24 expression may indicate the presence of different stem cell populations. Ocurrence of CD44+CD24- phenotype is more common in triple negative tumors and lower in tumors of luminal type and absent in HER2 tumors. Although not associated significantly with patho-biological markers or OS and DFS, the CD44+CD24- phenotype has a tendency to be a favorable prognostic marker in breast cancer raising the possibilty that the putative tumorigenic ability may no be restricted to cells of this phenotype. The presence of CD44-CD24+ may indicat a worse prognosis. CD24+ was associated with ER, PR, Ki67and showed a marginal association with CK18 and claudin-7. CD24 and Claudin-7 positivity were the only biological markers associated with reduced DFS. These two investigated markers can be used to improve the assessement of prognosis in breast cancer
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Haas, Karen Marie. "Induction and regulation of bovine B lymphocyte responses /." free to MU campus, to others for purchase, 2000. http://wwwlib.umi.com/cr/mo/fullcit?p9999290.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Schmitz, Paul. "Mechanismen immunologischer Toleranz nach Lebertransplantation : Untersuchungen zum Zytokinmuster intrahepatischer CD4+ CD45RCpos und CD4+ CD45RCneg T-Lymphozyten." Doctoral thesis, kostenfrei, 2007. http://nbn-resolving.de/urn/resolver.pl?urn=nbn:de:bvb:20-opus-26703.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Giordanengo, Valérie. "Glycoproteines lymphocytaires, infection vih et autoimmunite." Aix-Marseille 2, 1996. http://www.theses.fr/1996AIX20652.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Saeland, Sem. "Caractérisation et physiologie in vitro des cellules hématopoïétiques humaines exprimant l'antigène CD34." Lyon 1, 1992. http://www.theses.fr/1992LYO1H053.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Rose, Charlotte S. P. "CD4 antigen chimaeras of poliovirus." Thesis, University of Reading, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.240217.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "CD44 antigen"

1

Rahelu, Manjit. Characterisation of human CD4[superior plus] cytolytic T lymphocytes, with special reference to mycobacterial antigens. Birmingham: University of Birmingham, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

G, Janossy, Autran B, Miedema F, Commission of the European Communities., European Federation of AIDS Research., and Medical Research Council (Great Britain), eds. Immunodeficiency in HIV infection and AIDS. Basel: Karger, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Workshop on Mechanisms and Specificity of HIV Entry into Host Cells (1989 San Francisco, Calif.). Mechanisms and specificity of HIV entry into host cells. New York: Plenum Press, 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Girgrah, Nigel. Characterization of surface antigen CD44 on astrocytes in normal and diseased brain. 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

(Editor), Hari G. Garg, and Charles A. Hales (Editor), eds. Chemistry and Biology of Hyaluronan. Elsevier Science, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

(Editor), Hari G. Garg, and Charles A. Hales (Editor), eds. Chemistry and Biology of Hyaluronan. Elsevier Science, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

(Editor), B. Kyewski, and Elisabeth Suri-Payer (Editor), eds. CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential (Current Topics in Microbiology and Immunology). Springer, 2005.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

D, Stern Robert M., ed. Hyaluronan in cancer biology. San Diego, CA: Academic Press, 2009.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Mechanisms and Specificity of HIV Entry into Host Cells. Springer, 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "CD44 antigen"

1

Osada, Atsushi, Atsushi Saitoh, Nami Yasaka, Masutaka Furue, and Kunihiko Tamaki. "Expression of CD44 Antigen by Langerhans Cells and Thy1+ Dendritic Epidermal Cells - Ontogenetic Variation and Its Role in Migration." In Advances in Experimental Medicine and Biology, 117–19. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1971-3_25.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Canaday, David H. "Production of CD4+ and CD8+ T Cell Hybridomas." In Antigen Processing, 297–307. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-218-6_22.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Canaday, David H. "Erratum: Production of CD4+ and CD8+ T Cell Hybridomas." In Antigen Processing, E1. Totowa, NJ: Humana Press, 2017. http://dx.doi.org/10.1007/978-1-62703-218-6_43.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Matthis, Jessica, and Helena Reijonen. "Production of Primary Human CD4+ T Cell Lines and Clones." In Antigen Processing, 545–55. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-218-6_40.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Matthis, Jessica, Victoria King, and Helena Reijonen. "Production of Antigen-Specific Human CD4+ T Cell Lines and Clones." In Antigen Processing, 387–402. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9450-2_27.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kong, Ying Ying, and William W. Kwok. "Identification of Human Antigen-Specific CD4+ T-Cells with Peptide–MHC Multimer Technologies." In Antigen Processing, 375–86. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9450-2_26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Weiss, R. A., P. R. Clapham, and J. A. McKeating. "The Role of CD4 Antigen in HIV Infection." In Progress in Immunology, 1021–27. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83755-5_137.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Janeway, Charles A., Pilar Portoles, John P. Tite, Jose Rojo, Kaj Saizawa, and Barry Jones. "Recognition of MHC Class II Antigens by the CD4: T Cell Receptor Complex." In H-2 Antigens, 441–49. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4757-0764-9_44.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Banchereau, J., B. Dubois, J. Fayette, N. Burdin, F. Brière, P. Miossec, M. C. Rissoan, C. van Kooten, and C. Caux. "Functional CD40 Antigen on B Cells, Dendritic Cells and Fibroblasts." In Advances in Experimental Medicine and Biology, 79–83. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1971-3_16.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Mazerolles, Fabienne, F. Amblard, O. Lecomte, S. Meloche, C. Barbat, P. Hauss, C. Hivroz, R. Sekaly, and A. Fischer. "Regulation of Antigen-Independent Adhesion of CD4 T Cells." In Structure, Function, and Regulation of Molecules Involved in Leukocyte Adhesion, 228–31. New York, NY: Springer New York, 1993. http://dx.doi.org/10.1007/978-1-4613-9266-8_18.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "CD44 antigen"

1

Wernet, P., E. M. Scheider, P. Sarin, P. Chandra, H. H. Brackmann, M. Kessler, and H. Egli. "Demonstration of HIV-encoded Proteins in Cultured and in Uncultured CD 4 Positive Mononuclear Cells from Hemophilia Patients Employing Monoclonal Antibodies against p 15, p 24, GP 41, GP 120, and Reverse Transcriptase." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644683.

Повний текст джерела
Анотація:
In the light of the large percentage of hemophilia patients with antibodies to HIV the identification of a specific virus infection in comparison to HIV antibody negative hemophilia patients has reached crucial importance. The low success rates of direct virus culture techniques together with the as yet low AIDS-di-sease rate observed in these patients separate these patients from the other main risk groups. Within this context, we studied the expression of CD3, CD4, CD8, and HLA class II antigens on fixed cells after PHA stimulation and Interleukin 2 propagation as well as on untreated blood mononuclear cells from healthy individuals and from hemophilia patients by fluorescence activated flow cytometry. Monoclonal antibodies thought to be specific for p 15, p 24, GP 41, GP 120, and for reverse transcriptase revealed a certain number of positive cells on all defined subpopulations analysed. From cell specimen of HIV antibody positive hemophilia patients cells with specific HIV antigens could be enriched by in vitro cultivation. Importantly the expression of virus-encoded antigens preceedes a cytopathic effect for several daVs. Current analyses aim at the prognostic relevance of low amounts of such viral HIV proteins selectively detectable by moAbs.directed to either p 24, GP 41, GP 120, and RT. The reliability, high sensitivity and monoclonal antibody dependent specificity of this newly developed method for the demonstration of HIV specific proteins make it applicable also for longitudinal surveys of hemophilia patients to assess a potential state of viremia or virus antigen processing in their mononuclear cells.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Foster, Aaron, Joanne Shaw, Matthew Collinson-Pautz, Aruna Mahendravada, Christine Gagliardi, Mariam Khalil, Patrick Paczkowski, Sean Mackay, and Jing Zhou. "Abstract 898: Single-cell multiplex proteomics reveals synergistic activity of antigen and MyD88/CD40 stimulatory signals on promoting polyfunctional chimeric antigen receptor T cells." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-898.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Razawy, W., N. Salioska, P. Asmawidjaja, A. M. Mus, M. Van Meurs, I. Haspels-Brouwers, N. Kops, M. Oukka, V. Kuchroo, and E. Lubberts. "THU0032 Ccr6+cd4+ t cells drive antigen-induced arthritis via the il-23r pathway." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.6385.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Haque, Azizul, Duncan Norton, Bently Doonan, and Shereen Amria. "Abstract 4787: GILT regulates antigen processing and CD4+ T cell recognition of melanoma cells." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4787.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Al Heialy, S., B. Tolloczko, K. Tsuchiya, S. Siddiqui, D. Ramos-Barbon, and JG Martin. "Antigen-Specific CD4+ T Cells Drive Airway Smooth Muscle Proliferation through the Epidermal Growth Factor Receptor." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5598.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Filbert, Erin L., Pia Björck, Xiaodong Yang, and Ovidiu C. Trifan. "Abstract 4867: The CD40 agonistic antibody APX005M ‘licenses’ antigen presenting cells to promote tumor-specific T-cell responses." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4867.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Charles, Nichola, Jared Kanofsky, Jane L. Liesveld, and Michael R. King. "Using Protein-Functionalized Microchannels for Stem Cell Separation." In ASME 4th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2006. http://dx.doi.org/10.1115/icnmm2006-96228.

Повний текст джерела
Анотація:
Current hematopoietic stem cell (HSC) separation methods utilize immunomagnetic techniques where antibodies are conjugated to paramagnetic or iron-dextran particles so that the cells can be precipitated using a magnetic field. Antibodies are usually targeted against CD34 antigen, a known HSC marker that is lost as the cell matures into a terminally differentiated blood cell. While this method is able to produce stem cell purities greater than 80% in most cases, cell yield is usually low (<50%) and there is evidence to suggest that not all HSCs express CD34 and hence, cannot be selected using these methods. Our long-term aim is to move away from immunologic isolation methods and instead focus on general HSC behavior in the presence of specific proteins. Selectins are a group of adhesion molecules that have been shown to selectively retard HSC rolling in comparison to more mature blood cells so that, under the right conditions, HSC isolation from whole blood should be possible. Since this functional method is independent of specific HSC surface marker, it would enable isolation of all HSC sub-populations as well as improve the overall yield. We have used two geometries for HSC isolation using selectins. The first assembly was a commercially available parallel plate flow chamber with rectangular cross-section. This proved to be inefficient for cell separation due to the emergence of dead zones within the chamber and excessive cell accumulation along the tubing and fittings that comprised the inlets and outlets. We have evaluated this chamber and two redesigns using finite elements software. Ultimately we decided on a simpler approach — to replace the flow chamber with a capillary tube, which reduced unwanted cell accumulation due to gravity or dead zones while increasing the effective area for separation, and hence allowing for better HSC isolation.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Merz, Christian, Jaromir Sykora, Viola Marschall, David M. Richards, Meinolf Thiemann, Harald Fricke, Oliver Hill, and Christian Gieffers. "Abstract 1760: The hexavalent CD40 agonist HERA-CD40L augments multi-level crosstalk between T cells and antigen-presenting cells." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1760.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Gardyan, Adriane, Wolfram Osen, Maria Agawal, Inka Zörnig, Eliana Ruggiero, Manfred Schmidt, Andreas Schneeweiss, Dirk Jäger, and Stefan B. Eichmüller. "Abstract 3154: Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3154.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Poynter, ME, and SA Paveglio. "Indoleamine 2,3-Dioxygenase Activity in Airway Epithelial Cells Reduces Antigen-Specific CD4+T Cell Cytokine Production afterAspergillus fumigatusExposure." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4296.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "CD44 antigen"

1

Perelson, Alan S., and Robertus de Boer. Antigen-stimulated CD4 T cell expansion can be limited by their grazing of peptide-MHC complexes. Office of Scientific and Technical Information (OSTI), December 2012. http://dx.doi.org/10.2172/1058057.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "CD44 antigen" для конкретних типів джерел:
Статті в журналах Дисертації
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії